查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1682053

2025年披衣菌感染披衣菌（CT）和淋病奈瑟菌（NG）检测全球市场报告

Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 200 Pages | 商品交期: 2-10个工作天内

价格
简介目录

披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场规模预计将在未来几年内快速成长。预计到 2029 年将成长至 33.3 亿美元，复合年增长率为 10.9%。预测期内的成长归因于远端医疗和远端医疗、个人化医疗方法、就地检验的扩展以及人口健康管理策略。预测期内的主要趋势包括快速 POC 测试、个人化测试方法、多疾病测试平台、社区测试和推广计划的扩展。

性行为感染感染（STI）的日益普及预计将在短期内推动披衣菌感染衣原体（CT）和淋病奈瑟菌（NG）检测市场的成长。性行为感染传染病是透过性接触传播的细菌、病毒或寄生虫感染疾病，由于性教育不足、性活动活性化、社会耻辱和获取障碍等因素而呈上升趋势。 CT和NG检查在性传染感染的发现和管理中发挥重要作用，有助于早期诊断、治疗和预防传播。例如，根据世界卫生组织（WHO）2023年7月的报告，全球每天有超过一百万例新的性传染感染病例，估计每年有3.74亿例新感染病例，占可治疗性传染感染病例的四分之一。因此，性行为感染传染病的流行凸显了CTNG检测市场的成长轨迹。

披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场的关键参与者正在优先开发创新检测解决方案，以满足对抗击性传播感染的准确和可扩展检测方法日益增长的需求。其中一个解决方案是 BD COR MX/PX 系统，这是一个高通量感染疾病分子诊断平台。这种先进的检测设备旨在快速分析大量检体的感染疾病病原体。 BD COR MX/PX 系统由 Becton Dickinson 于 2022 年 5 月推出，简化了处理大量传染病检查（包括 CT 和 NG 测试）的实验室的工作流程。该平台可以使用机器人和软体演算法来自动化整个测试过程，提高效率并缩短等待测试结果的时间。显着的特点包括自动化、高通量能力、双 DNA 标靶以及模组化、可扩展的设计。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场 - 宏观经济情景，包括利率、通膨、地缘政治、新冠疫情以及復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测 PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素、限制因素）
  • 最终用途产业分析
  • 全球披衣菌感染衣原体（CT）和淋病奈瑟菌（NG）检测市场：成长率分析
  • 全球披衣菌感染衣原体 (CT) 与淋病奈瑟菌 (NG) 检测市场表现：规模与成长，2019-2024 年
  • 全球披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场预测：规模与成长，2024-2029 年，2034 年预测
  • 全球披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测总目标市场 (TAM)

第六章市场区隔

  • 全球披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场（按检测类型、性能和预测），2019-2024 年、2024-2029 年、2034 年
  • 实验室
  • 就地检验
  • 全球披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场（按产品、性能和预测）2019-2024 年、2024-2029 年、2034 年
  • 检测方法和套件
  • 仪器或分析设备
  • 全球披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场（按技术、性能和预测），2019-2024 年、2024-2029 年、2034 年
  • 恒温核酸增幅技术
  • 聚合酵素链锁反应
  • 免疫诊断
  • 其他技术
  • 全球披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场（按最终用户、绩效和预测）2019-2024 年、2024-2029 年、2034 年
  • 诊断实验室
  • 医院和诊所
  • 其他最终用户
  • 全球披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场，按实验室细分、类型、绩效和预测，2019-2024 年、2024-2029 年、2034 年
  • 核酸增幅检查（NAAT）
  • 聚合酵素链锁反应（PCR）检测
  • 酵素免疫分析法（ELISA）
  • 萤光试验（IFA）
  • 文化测试
  • 直接萤光抗体（DFA）检测
  • 全球披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场，按就地检验类型细分，性能和预测，2019-2024 年、2024-2029 年、2034 年
  • 快速诊断测试（RDT）
  • 横向流动化验
  • 层析法检测
  • 自检检测套组
  • 环介导等温扩增（LAMP）
  • 基于微流体的测试

第七章 区域和国家分析

  • 全球披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场各地区表现及预测（2019-2024 年、2024-2029 年及 2034 年）
  • 全球披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场（按国家/地区划分）、绩效及预测（2019-2024 年、2024-2029 年预测、2034 年预测）

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章竞争格局与公司概况

  • 披衣菌感染披衣菌 (CT) 与淋病奈瑟菌 (NG) 检测市场：竞争格局
  • 披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场：公司简介
    • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

  • Siemens Healthineers
  • Becton Dickinson and Company
  • Grifols SA
  • Hologic Inc
  • PerkinElmer
  • bioMerieux
  • Sysmex Corporation
  • Bio-Rad Laboratories
  • QIAGEN
  • Quidel Corporation
  • DiaSorin
  • Cepheid
  • Seegene Inc
  • Meridian Bioscience Inc
  • Sekisui Diagnostics

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

  • 2029 年披衣菌感染披衣菌 (CT) 和淋病奈瑟菌 (NG) 检测市场：提供新机会的国家
  • 2029 年披衣菌感染披衣菌 (CT) 和淋病奈瑟菌 (NG) 检测市场：细分市场带来新机会
  • 披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场 2029 年：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第36章 附录

简介目录
Product Code: r27659

Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) testing involves diagnosing sexually transmitted infections (STIs) caused by these bacteria in sexually active individuals, particularly those with multiple partners or engaging in unprotected sexual activity. These tests aim to identify the presence of CT and NG bacteria through various methods such as urine samples, genital area swabs, or blood tests.

The primary testing methods for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are laboratory testing and point-of-care testing. Laboratories are specialized facilities equipped with trained personnel and specialized equipment to conduct CT and NG testing on patient samples. This includes a range of products such as assays, kits, instruments, and analyzers utilizing various technologies such as isothermal nucleic acid amplification technology, polymerase chain reaction, immunodiagnostics, among others. End users of these laboratory services include diagnostic laboratories, hospitals, clinics, and other healthcare facilities.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market research report is one of a series of new reports from The Business Research Company that provides chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market statistics, including chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing industry global market size, regional shares, competitors with a chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market share, detailed chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market segments, market trends and opportunities, and any further data you may need to thrive in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing industry. This chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market size has grown rapidly in recent years. It will grow from $1.98 billion in 2024 to $2.2 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to emergence of antibiotic resistance, awareness campaigns and education, policy changes.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market size is expected to see rapid growth in the next few years. It will grow to $3.33 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to telemedicine and telehealth, personalized medicine approaches, point-of-care testing expansion, population health management strategies. Major trends in the forecast period include expansion of rapid point-of-care testing, personalized testing approaches, multi-disease testing platforms, community-based testing and outreach programs.

The escalating prevalence of sexually transmitted infections (STIs) is anticipated to drive the expansion of the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in the foreseeable future. STIs, resulting from bacterial, viral, or parasitic infections transmitted through sexual contact, are on the rise due to factors such as inadequate sex education, heightened sexual activity, societal stigma, and accessibility barriers. CT and NG testing plays a crucial role in the detection and management of STIs, facilitating early diagnosis, treatment, and prevention of transmission. For instance, as reported by the World Health Organization in July 2023, over 1 million new STIs are contracted daily worldwide, with an estimated 374 million new infections occurring annually, encompassing one in four treatable STIs. Consequently, the escalating prevalence of sexually transmitted infections underscores the growth trajectory of the CTNG testing market.

Key players in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are prioritizing the development of innovative testing solutions to address the growing need for accurate and scalable testing methods to combat STIs. One such solution is the BD COR MX/PX System, a high-throughput infectious disease molecular diagnostic platform. This sophisticated laboratory instrument is designed to rapidly analyze large numbers of samples for infectious agents. Launched by Becton Dickinson and Company in May 2022, the BD COR MX/PX System streamlines workflow in labs processing numerous infectious disease tests, including CT and NG testing. The platform automates the entire testing process using robotics and software algorithms, enhancing efficiency and potentially reducing wait times for test results. Notable features include automation, high-throughput capability, dual DNA targets, and a modular and scalable design.

In December 2023, Imaware, a US-based health testing company, acquired the consumer testing business from Binx Health for an undisclosed amount. This acquisition enables Imaware to expand its consumer diagnostics portfolio, increasing access to STI screenings and other health tests. Binx Health is a US-based company specializing in at-home and point-of-care diagnostic testing solutions, with a focus on sexual health.

Major companies operating in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers, Becton Dickinson and Company, Grifols SA, Hologic Inc., PerkinElmer, bioMerieux, Sysmex Corporation, Bio-Rad Laboratories, QIAGEN, Quidel Corporation, DiaSorin, Cepheid, Seegene Inc., Meridian Bioscience Inc., Sekisui Diagnostics, J. Mitra & Co. Pvt. Ltd., Atlas Medical, Hardy Diagnostics, Molbio Diagnostics Pvt. Ltd., NG Biotech

North America was the largest region in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in 2024. The regions covered in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market includes revenues earned by entities by providing services such as diagnostic testing, sample collection, laboratory analysis, and confidential counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market also includes the sale of sample collection kits, control materials, laboratory equipment, and software solutions. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Test Type: Laboratory; Point Of Care Testing
  • 2) By Product: Assays And Kits; Instruments Or Analyzers
  • 3) By Technology: Isothermal Nucleic Acid Amplification Technology; Polymerase Chain Reaction; Immunodiagnostics; Other Technologies
  • 4) By End User: Diagnostic Laboratories; Hospitals And Clinics; Other End Users
  • Subsegments:
  • 1) By Laboratory: Nucleic Acid Amplification Tests (NAAT); Polymerase Chain Reaction (PCR) Tests; Enzyme-Linked Immunosorbent Assay (ELISA); Immunofluorescence Assay (IFA); Culture Tests; Direct Fluorescent Antibody (DFA) Tests
  • 2) By Point Of Care Testing: Rapid Diagnostic Tests (RDT); Lateral Flow Assays; Immunochromatographic Tests; Self-Testing Kits; Loop-Mediated Isothermal Amplification (LAMP); Microfluidics-Based Tests
  • Companies Mentioned: F. Hoffmann-La Roche AG; Thermo Fisher Scientific; Abbott Laboratories; Danaher Corporation; Merck KGaA
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Characteristics

3. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Trends And Strategies

4. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Growth Rate Analysis
  • 5.4. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Total Addressable Market (TAM)

6. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Segmentation

  • 6.1. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Laboratory
  • Point Of Care Testing
  • 6.2. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Assays And Kits
  • Instruments Or Analyzers
  • 6.3. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Isothrmal Nucleic Acid Amplification Technology
  • Polymerase Chain Reaction
  • Immunodiagnostics
  • Other Technologies
  • 6.4. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Diagnostic Laboratories
  • Hospitals And Clinics
  • Other End Users
  • 6.5. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Sub-Segmentation Of Laboratory, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Nucleic Acid Amplification Tests (NAAT)
  • Polymerase Chain Reaction (PCR) Tests
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunofluorescence Assay (IFA)
  • Culture Tests
  • Direct Fluorescent Antibody (DFA) Tests
  • 6.6. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Sub-Segmentation Of Point Of Care Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Rapid Diagnostic Tests (RDT)
  • Lateral Flow Assays
  • Immunochromatographic Tests
  • Self-Testing Kits
  • Loop-Mediated Isothermal Amplification (LAMP)
  • Microfluidics-Based Tests

7. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Regional And Country Analysis

  • 7.1. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 8.1. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 9.1. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 9.2. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 10.1. India Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 11.1. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 11.2. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 12.1. Australia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 13.1. Indonesia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 14.1. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 14.2. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 15.1. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 15.2. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 16.1. UK Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 17.1. Germany Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 18.1. France Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 19.1. Italy Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 20.1. Spain Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 21.1. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 21.2. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 22.1. Russia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 23.1. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 23.2. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 24.1. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 24.2. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 25.1. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 25.2. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 26.1. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 26.2. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 27.1. Brazil Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 28.1. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 28.2. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 29.1. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 29.2. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Competitive Landscape And Company Profiles

  • 30.1. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Competitive Landscape
  • 30.2. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis

31. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Other Major And Innovative Companies

  • 31.1. Siemens Healthineers
  • 31.2. Becton Dickinson and Company
  • 31.3. Grifols SA
  • 31.4. Hologic Inc
  • 31.5. PerkinElmer
  • 31.6. bioMerieux
  • 31.7. Sysmex Corporation
  • 31.8. Bio-Rad Laboratories
  • 31.9. QIAGEN
  • 31.10. Quidel Corporation
  • 31.11. DiaSorin
  • 31.12. Cepheid
  • 31.13. Seegene Inc
  • 31.14. Meridian Bioscience Inc
  • 31.15. Sekisui Diagnostics

32. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

34. Recent Developments In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

35. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market High Potential Countries, Segments and Strategies

  • 35.1 Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer